Abstract Background: Lung inflammatory diseases (such as asthma and chronic obstructive pulmonary disease COPD)) are widespread inflammatory airway illnesses that are characterized by cough, wheezing, chest tightness, and dyspnea, all of which are symptoms of airway obstruction. Objective: To investigate how famotidine influences pro-inflammatory cytokines (IL-4, IL-6, TNF- α , and IL-10) related to airway inflammation. Materials and Methods: Thirty healthy male albino rats weighing 150 and 200 g were divided into five groups of six rats each as follows: A Group: Control group—rats received distilled water for a period of 14 days. B Group: Positive control group—rats were exposed to airway sensitization. C Group: Rats were treated with oral prednisolone at a dose of 4.12 mg/kg, after exposure to airway sensitization. D Group: Rats received oral famotidine (20 mg/kg) after airway sensitization. E Group: Rats received oral prednisolone and famotidine (4.12 mg/kg and 20 mg/kg), respectively, after airway sensitization. Inflammatory cytokines of rats (IL-4, IL-6 IL-10, and TNF- α ) were measured by ELISA after 14 days of study. Results: The levels of inflammatory cytokines such as IL-4, IL-6, and TNF- α were reduced after famotidine treatment, indicating that famotidine has anti-inflammatory properties. Conclusion: According to the current study, famotidine, as an antagonist of the histamine-2 receptor, has demonstrated anti-inflammatory properties in an airway model. This has been observed through decreased levels of crucial pro-inflammatory cytokines such as IL-4, IL-6, and TNF- α , in addition to an increase in IL-10 level. More research with famotidine could be conducted in future to prevent and treat other inflammatory respiratory illnesses.
Hasan et al. (Thu,) studied this question.